Health Care & Life Sciences » Pharmaceuticals | Komipharm International Co. Ltd.

Komipharm International Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
26,465
34,454
36,405
37,636
36,641
Cost of Goods Sold (COGS) incl. D&A
17,731
23,945
26,824
28,187
26,600
Gross Income
8,734
10,509
9,581
9,449
10,041
SG&A Expense
8,226
10,282
10,090
8,772
10,124
EBIT
472
178
567
609
150
Unusual Expense
666
2,253
1,636
620
4,228
Non Operating Income/Expense
370
243
5,884
1,242
630
Interest Expense
1,179
2,160
1,440
1,453
1,349
Pretax Income
1,563
3,684
9,368
94
7,815
Income Tax
1,480
1,535
2,821
349
2,619
Equity in Affiliates
-
-
-
28
-
Consolidated Net Income
82
2,150
6,548
227
5,196
Net Income
82
2,150
6,548
289
5,096
Net Income After Extraordinaries
82
2,150
6,548
289
5,096
Net Income Available to Common
82
2,150
6,548
289
5,096
EPS (Basic)
2.00
44.00
125.00
5.00
94.00
Basic Shares Outstanding
49
49
52
54
54
EPS (Diluted)
1.68
43.56
125.28
5.34
93.51
Diluted Shares Outstanding
49
49
52
54
54
EBITDA
1,523
2,140
2,067
3,943
3,361
Other Operating Expense
35
50
58
67
67
Non-Operating Interest Income
180
308
159
128
485
Minority Interest Expense
-
-
-
62
100
Equity in Affiliates (Pretax)
-
-
-
-
1,942

About Komipharm International Co.

View Profile
Address
17 Gyeongje-ro
Siheung GY 15094
Korea, Republic Of
Employees -
Website http://www.komipharm.com
Updated 09/14/2018
Komipharm International Co., Ltd. engages in the development and manufacturing of natural food additives, veterinary vaccines and pharmaceuticals. It operates through Animal Health and Pharmaceuticals divisions. The Animal Health division manufactures veterinary products such as vaccines, antibiotics, antibacterial, nutrition, metabolic, immune boosters, digestive enzymes, expectorant, hormone, skin disease, anesthetic, antipyretic-analgesics and organic acid for being used to livestock, aqua and pet animals.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.